Denmark-based Xellia Pharmaceuticals, a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has held an official ground breaking ceremony for a new $25 million expansion at its Copenhagen site.
This site houses Xellia’s headquarters and is the company’s largest product manufacturing plant. Since 2013, Xellia is a wholly-owned by Novo Holdings A/S, which is also a major shareholder in Danish diabetes care giant Novo Nordisk (NOV: N).
Xellia’s Copenhagen site is responsible for manufacturing, stability testing and packaging of both sterile active pharmaceutical ingredients (APIs) and the finished dosage forms (FDFs) for anti-infectives such as vancomycin, and colistimethate sodium.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze